LAVA Therapeutics NV (LVTX)
2.26
-0.14
(-5.83%)
USD |
NASDAQ |
May 31, 16:00
2.28
+0.02
(+0.88%)
After-Hours: 20:00
LAVA Therapeutics Enterprise Value: -29.86M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | -29.86M |
| May 30, 2024 | -26.18M |
| May 29, 2024 | -26.70M |
| May 28, 2024 | -26.44M |
| May 24, 2024 | -19.87M |
| May 23, 2024 | -19.87M |
| May 22, 2024 | -17.76M |
| May 21, 2024 | -19.60M |
| May 20, 2024 | -18.29M |
| May 17, 2024 | -19.87M |
| May 16, 2024 | -16.71M |
| May 15, 2024 | -14.87M |
| May 14, 2024 | -13.29M |
| May 13, 2024 | -8.824M |
| May 10, 2024 | -8.035M |
| May 09, 2024 | -7.509M |
| May 08, 2024 | -8.298M |
| May 07, 2024 | -10.40M |
| May 06, 2024 | -14.61M |
| May 03, 2024 | -9.613M |
| May 02, 2024 | -7.772M |
| May 01, 2024 | -11.19M |
| April 30, 2024 | -13.29M |
| April 29, 2024 | -13.03M |
| April 26, 2024 | -17.50M |
| Date | Value |
|---|---|
| April 25, 2024 | -19.87M |
| April 24, 2024 | -17.24M |
| April 23, 2024 | -10.93M |
| April 22, 2024 | -14.35M |
| April 19, 2024 | -18.03M |
| April 18, 2024 | -14.87M |
| April 17, 2024 | -11.98M |
| April 16, 2024 | -13.29M |
| April 15, 2024 | -12.24M |
| April 12, 2024 | -6.983M |
| April 11, 2024 | -1.462M |
| April 10, 2024 | -9.350M |
| April 09, 2024 | -18.03M |
| April 08, 2024 | -11.72M |
| April 05, 2024 | -9.087M |
| April 04, 2024 | -13.82M |
| April 03, 2024 | -7.509M |
| April 02, 2024 | -7.246M |
| April 01, 2024 | -0.6733M |
| March 31, 2024 | -1.725M |
| March 28, 2024 | -2.746M |
| March 27, 2024 | 12.50M |
| March 26, 2024 | 15.66M |
| March 25, 2024 | 7.244M |
| March 22, 2024 | 5.666M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-86.43M
Minimum
Mar 27 2023
350.32M
Maximum
Mar 25 2021
-5.570M
Average
-19.87M
Median
Apr 25 2024
Enterprise Value Benchmarks
| uniQure NV | -214.21M |
| ProQR Therapeutics NV | 53.04M |
| Merus NV | 2.787B |
| argenx SE | 18.88B |
| Pharming Group | 549.11M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.553M |
| Revenue (Quarterly) | 6.992M |
| Total Expenses (Quarterly) | 8.944M |
| EPS Diluted (Quarterly) | -0.02 |
| Profit Margin (Quarterly) | -7.91% |
| Earnings Yield | -46.90% |
| Normalized Earnings Yield | -47.12 |